However, a recent study reveals that pharmacological inhibition of EPHX2, as well as dietary w-3 PUFA supplementation in different murine cancer models, can improve cancer immunotherapy against immune checkpoints such as PD-1 and CTLA [43]. The gene discussed is EPHX2; the disease is cancer.